{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-018580","form_type":"8-K","ticker":"HSDT","cik":"0001610853","company_name":"Solana Co","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.774218+00:00","generated_at":"2026-06-08T06:43:50.720655+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Helius Medical Q3 revenue $143K, net loss $3.7M; cash runway into Q2 2024","bullets":["Q3 revenue $143K vs $196K YoY; decline due to PTAP expiration on June 30.","Net loss $3.7M vs $1.0M; basic EPS loss $5.49 vs $2.90.","Cash $6.6M plus $0.4M in warrant proceeds; operating burn $2.5M; runway into Q2 2024.","Received UPC codes for PoNS system ($25,700) and mouthpiece ($7,900) from Medi-Span.","Quebec MSSS LOI for up to 30 PoNS systems; UdeM order for 10 systems."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-018580","json":"https://secwatch.observer/filing/0001558370-23-018580.json","markdown":"https://secwatch.observer/filing/0001558370-23-018580.md","text":"https://secwatch.observer/filing/0001558370-23-018580.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1610853/000155837023018580/0001558370-23-018580-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1610853/000155837023018580/hsdt-20231109x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:43:50.720655+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7032460dfdc7a507d4ce3fc85c470bd9d3c6b3df","claim":"Solana Co reported the quarter ended September 30, 2023 results: revenue $143 thousand, net income Net loss was $3.7 million for the third quarter of 2023.","evidence_excerpt":"approach for balance and gait deficits, today announced results for the quarter ended September 30, 2023. Third Quarter and Recent Business Updates ● Q3 2023 revenue of $143 thousand, compared to $196 thousand in Q3 2022, the decrease due to the expiration of the Patient Therapy Access Program (“PTAP”) on June 30, 2023. ● Operating cash burn of $2.5 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1610853/000155837023018580/0001558370-23-018580-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Revenue","value":"$143 thousand"},{"label":"Net income","value":"Net loss was $3.7 million for the third quarter of 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}